Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2

BACKGROUND: Maraviroc, the first approved CCR5 antagonist, demonstrated 48-week safety and virologic efficacy in CCR5-tropic HIV-infected, treatment-experienced patients; however, critical longer-term safety and durability of responses are unknown. METHODS: Two-year follow-up of 2 prospective, rando...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hardy, W. David, Gulick, Roy M., Mayer, Howard, Fätkenheuer, Gerd, Nelson, Mark, Heera, Jayvant, Rajicic, Natasa, Goodrich, James
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3321258/
https://ncbi.nlm.nih.gov/pubmed/20703158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0b013e3181ee3d82
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados